UPDATE 2-British midcaps post weekly losses on Brexit woes, dour outlook

  • Reuters
  • Stock Market News
UPDATE 2-British midcaps post weekly losses on Brexit woes, dour outlook
Credit: © Reuters.

* AstraZeneca to run new global trial of COVID-19 vaccine - report

* JD Sports among worst performing bluechips this week

* Drugmaker Indivior underperforms midcaps for the week (Updates to close)

By Devik Jain and Ambar Warrick

Nov 27 (Reuters) - Domestically-oriented British midcap stocks rose slightly on Friday, but marked their first weekly loss this month as frictions in the Brexit process and a gloomy economic outlook due to the coronavirus weighed on sentiment.

The mid-cap FTSE 250 .FTMC rose 0.3% and lost 0.2% for the week, while the blue-chip FTSE 100 .FTSE ended the day and the week a touch higher.

The European Union and Britain said there were still substantial differences over a Brexit trade deal, with three main issues of contention - fishing, state aid and how to resolve any future disputes.

The EU chief negotiator prepared to travel to London in a last-ditch attempt to avoid a tumultuous divorce, with just five weeks left until the deadline for UK's exit. talks will be held over the weekend—but this is not yet the last possible moment for a deal, and a deal can (by EU tradition) only occur at the last possible moment," Paul Donovan, chief economist of UBS Global Wealth Management said.

Appetite for locally-focussed stocks was battered through the week by updates from the finance and health ministers over the COVID-19 pandemic's economic impact, while doubts over the efficacy of a leading vaccine candidate also weighed.

A Bloomberg report said AstraZeneca AZN.L was likely to run an additional global trial to assess the efficacy of its COVID-19 vaccine using a lower dosage, amid questions over the results of its late-stage study. individual stocks, retailer JD Sports Fashion JD.L was among the worst performing blue-chip stocks for the week in the face of strict restrictions on activity even after the end of a nationwide lockdown.

Drugmaker Indivior INDV.L underperformed its midcap peers for the week with a 23.9% loss after it was slapped with a 1.07 billion pound ($1.43 billion) claim by its former owner Reckitt Benckiser RB.L .

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or